S1914

Trial Overview

Official Title

A randomized Phase III Trial of Induction/consolidation Atezolizumab (NSC #783608) + SBRT Alone in High Risk, Early Stage NSCL

Study Purpose

To compare overall survival in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab

Diagnosis

Minimally invasive adenocarcinoma NSCLC

Eligibility

Stage I-IIA or Limited Stage III disease undergone a diagnostic CT and PET scan and biopsy, no nodal involvement, must be medically or surgically inoperable

Intervention

Treatment ARM A

Atezolizumab for 8 cycles and Stereotactic body radiation

Treament ARM B

Stereotactic radiation

For more information, visit Clinicaltrials.gov

Key Participation Requirements

Trial Location(s)

Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital

Gender

Male or Female

Age

19 years and older

Enrollment Status

Recruiting

Phase

Phase III